Idexx Laboratories price target raised to $600 from $545 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on Idexx Laboratories to $600 from $545 and keeps a Neutral rating on the shares. The company unveiled several product introductions ahead of this weekend’s VMX event, most notably the inVue Dx instrument, the analyst tells investors in a research note. The firm says that at first glance, inVue, which is used to detect cytologic changes in ear and blood samples, is an impressive platform, which solves a lot of the inadequacies of current methods. BofA cites peer multiple expansion for the target increase.